PVI
CDTX

Pura Vida Investments’s Cidara Therapeutics CDTX Stock Holding History

Pura Vida Investments’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,750
Closed -$1.87M – 72
2017
Q4 		$1.87M Buy
+13,750
New +$2.09M 0.78% 48
2017
Q3 		– Sell
-7,500
Closed -$1.13M – 92
2017
Q2 		$1.13M Buy
+7,500
New +$1.04M 0.45% 50

Other funds holding CDTX

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Pura Vida Investments's CDTX Position: Q1 2018 in Review

Pura Vida Investments sold out of Cidara Therapeutics (CDTX) in Q1 2018, closing a stake of 13,750 shares — an estimated $1.87M sold.

Pura Vida Investments first reported a position in CDTX in Q2 2017 and held it in 2 quarters. The position peaked at $1.87M in Q4 2017. 60 funds tracked by Wall St. Rank hold CDTX as of Q1 2018.

  • Pura Vida Investments reported no remaining Cidara Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Pura Vida Investments sold 13,750 Cidara Therapeutics shares in Q1 2018, an estimated $1.87M.
  • Pura Vida Investments first reported a position in Cidara Therapeutics in Q2 2017 and held it in 2 quarters.
  • Pura Vida Investments's Cidara Therapeutics position peaked at $1.87M in Q4 2017.
  • 60 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2018.

Based on Pura Vida Investments's 13F filing for Q1 2018, filed 14 May 2018.